Figure 7.
Evaluation of glecaprevir/pibrentasvir as a re-treatment option against ED43 DAA escape viruses. HCV infections (A) and NGS analysis of complete ORF sequences of viruses (B) after treatments with glecaprevir/pibrentasvir. DAA escape viruses that were not eradicated by other investigated DAA combinations, were all treated with glecaprevir/pibrentasvir. Concentrations of 4x-EC50 of glecaprevir in combination with 5x-EC50 of pibrentasvir were used. For details, see figure 5 legend. NGS, next-generation sequencing; ORF, open reading frame.